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Abstract
The ability to restore homeostasis upon environmental challenges has been proposed as a
measure for health. Metabolic profiling of plasma samples during the challenge response
phase should offer a profound view on the flexibility of a phenotype to cope with daily stress-
ors. Current data modeling approaches, however, struggle to extract biological descriptors
from time-resolved metabolite profiles that are able to discriminate between different pheno-
types. Thus, for the case of oxylipin responses in plasma upon an oral glucose tolerance
test we developed a modeling approach that incorporates a priori biological pathway knowl-
edge. The degradation pathways of arachidonic and linoleic acids were modeled using a re-
gression model based on a pseudo-steady-state approximated model, resulting in a
parameter A that summarizes the relative enzymatic activity in these pathways. Analysis of
the phenotypic parameters As suggests that different phenotypes can be discriminated ac-
cording to preferred relative activity of the arachidonic and linoleic pathway. Correlation
analysis shows that there is little or no competition between the arachidonic and linoleic
acid pathways, although they share the same enzymes.
Introduction
A healthy human body is able to continuously adapt to its environment by rebalancing meta-
bolic processes. This allows the body to restore homeostasis upon disturbances by daily stress-
ors, such as diet and exercise. There is a growing awareness that the flexibility of the metabolic
phenotype is a prerequisite for maintaining a healthy state [1] and metabolic phenotyping is re-
ceiving a great deal of attention [2,3,4,5].
The concept of metabolic resilience has also been adopted in a newly proposed definition
for health, which departs from the ability to cope and adapt to social, physical and emotional
challenges [6]. Loss of metabolic flexibility due to chronic stress, such as an unbalanced diet,
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form the basis of metabolic flexibility.
At present there is only limited insight into whether and how phenotypes can differ in com-
pensatory mechanisms to adapt to external stressors. There are also no quantitative phenotypi-
cal descriptors of metabolic flexibility. Recognition of phenotypes that differ in metabolic
flexibility calls for a systems approach that addresses both the multifactorial aspects and the dy-
namic nature of metabolic regulatory processes upon external stressors. Advances in metabolic
profiling now allow for broad coverage of the human metabolome. In combination with time-
resolved sampling during the response phase this should provide a detailed view on the flexibil-
ity of the metabolic phenotype. Current data modeling techniques, however, struggle to extract
quantitative phenotypical parameters from time-resolved metabolic profiles [7]. Modeling ap-
proaches to date do not take into account the fact that metabolites share pathways and that the
time responses upon a dietary challenge are determined by consecutive catabolic or anabolic
conversions [7].
We hypothesized that by incorporating such a priori biological knowledge, data modeling
can be guided to deliver phenotypical descriptors that bear direct biological relevance. Further-
more, we expect that such an approach can also cope with a limited number of volunteers and
sampling points [8].
In a recent study we observed significant inter-individual differences in the response of the
different oxylipins upon oral glucose tolerance test [9] and thus we selected this study to derive
quantitative descriptors of phenotypical pathway preferences. This was accomplished by build-
ing a regression model that incorporates both the time-resolved oxylipin concentrations and
the a priori knowledge on the degradation pathways of arachidonic and linoleic acid. We show
that the resulting parameters are adequate estimates of phenotypic descriptors of
oxylipin metabolism.
Overview of Oxylipins Metabolism
Oxylipins, in general, have been associated with the initiation and resolution of inflammation
and vascular function [10] and are of particular interest for our purpose, since they follow spe-
cific pathways depending on the activity of different enzymes.
A wealth of prior information on conversion pathways of oxylipins is already available [11].
Here we will focus on those oxylipins that are enzymatically generated by oxidation of arachi-
donic acid and linoleic acid [12,13].
Arachidonic acid (AA) is a polyunsaturated fatty acid (PUFA) formed by the 6Δ/5Δ desatur-
ase pathway from LA [14]. AA is metabolized by three enzymes: cyclooxygenase (COX)[15],
lipoxygenase (LOX) [16], and cytochrome P450 epoxygenases P450 (CYP) [17]. COX-1 and-2
convert AA to prostaglandin H2 (PGH2), the precursor of the series-2 prostanoids, which are
produced by a series of specific synthases during cell-specific conversion processes. The LOX en-
zymes 5-, 12- and 15-LOX convert AA to hydroperoxy eicosatetraenic acids (HpETEs), which
are subsequently reduced to 5(S)-, 12(S)- and 15(S)-HETE (hydroxyeicosatetraenoic acid), re-
spectively. Unlike other lipoxygenases, 5-LOX requires the presence of the 5-lipoxygenase acti-
vating protein (FLAP) for productive leukotriene synthesis in vivo [11]. The HETEs are further
reduced by hydroxyeicosatetraenoic dehydrogenase (HEDH) to oxo-eicosatetraenoic acids
(oxo-ETE). Cytochrome P450 converts AA to epoxyeicosatrienoic acid (EET) regioisomers,
which in turn are converted by soluble epoxide hydrolase (sEH) to dihydroxyeicosatrienoic
acids (DiHETrEs) [18].
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Linoleic acid (AA) is an essential PUFA and its metabolism follows pathways regulated by
LOX and CYP enzymes. The LOX pathway (involving 5- and 15-LOX) is responsible for oxida-
tion of LA to hydroperoxyoctadecadienoic acids (HpODE), which are then converted to hydro-
xyoctadecadienoic acids (HODEs) and further to oxo-octadecadienoic acids (oxo-ODE).
9(S)-HODE, 9(S)-HpODE and 13(S)-HpODE can also be converted to trihydroxyoctadecenoic
acids (9,12,13-TriHOME, 9,10,13-TriHOME). The CYP pathway leads to epoxyoctadecamo-
noenoic acids (EpOME), which are subsequently converted to dihydroxyoctadeca(mono)enoic
acids (DiHOME).
Materials and Methods
Study design
Details of the study have been previously described [5]. In brief, 12 healthy adults (six males,
six females; age, 54 ± 6 years; BMI, 22 ± 1 kg/m2; and waist circumference, 80 ± 8 cm) partici-
pated in a crossover study including four test days separated by six washout days each. On each
test day, a different dietary challenge was tested. One of the dietary challenges was an oral glu-
cose tolerance test (OGTT), in which the subjects consumed 75 g of glucose (300 kcal) dis-
solved in 300 ml of water.
On each test day, the subjects arrived at the research facility in the morning after an over-
night fast of 10 hours. After the collection of baseline blood samples (t = 0), subjects consumed
one of the challenge test products within 10 min. Blood samples for oxylipin analysis were col-
lected at regular time points (0, 2, 4, 6, 8, 10 h) up to 10 h. No other foods or beverages were al-
lowed during the day, except water.
The study protocol was approved by the independent Medical Ethics Committee of
TNOMETOPP (Tilburg, the Netherlands) and all subjects gave written informed consent.
Data is available through the Nutritional Phenotype database (http://studies.dbnp.org/
ADMIT_01) [19].
Experimental methods
Sample collection and preparation. Blood samples were collected in tubes containing
EDTA as anticoagulant. Whole blood was centrifuged for 10 min at 4°C at 13,000 rpm within
15 min of collection. Serum and plasma were immediately separated, aliquoted and stored at
-80°C. For the oxylipin analysis, an inhibitor cocktail consisting of butylated hydroxytoluene,
indomethacin, paraoxon and phenylmethylsulfonyl fluoride was directly added to the plasma
samples (250 μL) before storage.
LC-MS/MS analysis. Oxylipins were analyzed on a UPLC coupled to a Xevo TQ-S mass
spectrometer (Waters) according to a previously described procedure [9,20]. In short, methanol
extracts of 250 μl of plasma sample were concentrated using solid-phase extraction columns.
The concentrated elutes were injected on a UPLC column and separated using gradient elution.
The gradient started with 95% A (MQ water with 0.1% FA) and 5% B (ACN with 0.1% FA) fol-
lowed by a linear increase to 70% A and 30% B. This was followed by a linear increase towards
50% B, and subsequently a switch to 100% B, which was maintained until the end of the run.
The column was maintained at 323.15 K during analysis, and the samples were kept at 283.15.
The MS was operating in selective reaction mode using electrospray ionization in negative ion
mode. Peak identification and quantification were performed using the MassLynx software ver-
sion 4.1. All calibration curves were run in duplicate, from which one regression equation was
generated. Quality control samples were included in each analytical run to check the quality of
the analysis and to correct for accuracy. From the comprehensive profile of oxylipins that was
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covered by the LC-MS/MS platform only 22 oxylipins were detected in an initial batch of
pooled samples. Hence only these oxylipins were selected for further processing.
Modeling techniques
Network simplification. We focused on AA and LA metabolism, a subset of the larger
oxylipin metabolic network. The metabolic routes of AA and LA were lumped to a simplified
network to include only the metabolites that showed a clear response upon OGTT according to
the following three rules, as commonly done in chemical reaction kinetics, metabolic engineer-
ing and systems biology [21,22]:
1. Multistep reactions with unmeasured intermediate metabolites were simplified to a single-
step reaction, for instance, the multistep reaction AA! 5-HpETE! 5-HETE is lumped to
AA! 5(S)-HETE;
2. Multistep reactions with intermediate metabolites that did not show any variation were sim-
plified to a single-step reaction, for instance, the reaction AA! 11,12-EET! 12,12-
DiHETrE is lumped to AA! 12,12-DiHETrE as 11,12-EET showed no or little variation;
3. Metabolites involved in unmeasured branches of the metabolic pathways were lumped to a
generic degradation reaction, for instance, compounds originating from 5(S)-HETE are set
to unmeasured in our lumped network.
The resulting lumped networks for AA and LA are shown in Fig. 1, panels A and B respec-
tively. Enzymes regulating metabolite degradation were not measured.
Data overview. The lumping of the metabolic networks of AA and LA leads to a simplified
version of the metabolic networks where four metabolites (5(S)-HETE; 15(S)-HETE; 11,12-
DiHETrE; 14,15-DiHTrE) were retained for AA, and three for LA (9(S)-HODE; 9,10-
DiHOME; 13(S)-HODE). The study design involved 12 subjects from whom blood samples for
oxylipin analysis were taken at regular time points (0, 2, 4, 6, 8, 10 h). Fig. 2 and 3 provide an
overview of the changes in concentration of 11,12-DiHETrE and 9,10-DiHOME over time for
the 12 subjects, respectively. Although the time curves follow similar patterns, differences be-
tween the subjects can be observed. Data covers a relatively long time period, but it should be
noted that information is not evenly spread over the eight time points. Only the second mea-
surement at 2 h strongly differed from the rest of the measurements. Modeling this kind of
data characterized by a paucity of information is challenging; the following sections propose a
strategy to tackle this problem.
Mathematical models
A deterministic model in the form of a mathematical function-based model is devised whose
mathematical parameters are to be estimated from the experimental data available. The mathe-
matical model must be conceived on the basis of a priori biological knowledge in a way that the
parameters can be estimated from the experimental data available. In the case of AA and LA
metabolism, the biochemical process is known and described by the network structure of a degra-
dation pathway that can be translated into a system of mathematical (kinetic) equations. Depend-
ing on the assumptions, different mathematical models can be considered.
Model 1: System of ordinary differential equations. Given the underlying biochemistry,
the model is given by a system of ordinary differential equations (ODEs). With reference to
panels A and B of Fig. 1, the corresponding systems of ODEs for the AA metabolic pathway
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are given by the equations
d½5ðSÞ HETE
dt
¼ k1½AA  k8½5ðSÞ HETE
d½15ðSÞ HETE
dt
¼ k2½AA  k9½15ðSÞ HETE
d½11; 12 DiHETrE
dt
¼ k3½AA  k10½11; 12 DiHETrE
d½14; 15 DiHETrE
dt
¼ k4½AA  k11½14; 15 DiHETrE
8>>>>>><
>>>>>>:
ð1Þ
Fig 1. Lumped networks for oxylipins metabolism. Lumped networks for arachidonic (panel A) and linoleic (panel B) acid metabolism. Abbreviations:
Dihydroxyeicosatrienic acid (DiHETrE); Dihydroxyoctadecenoic acid (DiHOME); Hydroxyeicosatetraenoic acid (HETE); Hydroxyoctadienoic acid (HODE).
The rationale underlying the lumping strategy is described in Section: Network simplification.
doi:10.1371/journal.pone.0119856.g001
Individual Phenotyping Using an Oral Glucose Tolerance Test
PLOS ONE | DOI:10.1371/journal.pone.0119856 March 18, 2015 5 / 16
Fig 2. Concentration profiles for 11,12-DiHeTrE.Measured (black dots) and fitted (red dots) time concentration profiles for 11,12-DiHeTrE (AA
metabolism) for 12 subjects. The regression parameter A, lumping the coefficients P and D (dimension t-1) describing the production rate and the degradation
rate for 11,12-DiHeTrE (see Equation (3)) is obtained under a pseudo-steady-state approximation (Equation (4)) and obtained via Equation (7).
doi:10.1371/journal.pone.0119856.g002
Fig 3. Concentration time profiles for 9,10-DiHOME.Measured (black dots) and fitted (red dots) time concentration profiles for 9,10-DiHOME (AA
metabolism) for 12 subjects. The regression parameter A, lumping the coefficients P and D (dimension t-1) describing the production rate and the degradation
rate for 9,10-DiHOME (see Equation (3)) is obtained under a pseudo-steady-state approximation (Equation (4)) and obtained via Equation (7).
doi:10.1371/journal.pone.0119856.g003
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and for LA by
d½9ðSÞ HODE
dt
¼ k5½LA  k12½9ðSÞ HODE
d½9; 10 DiHOME
dt
¼ k6½LA  k13½9; 10 DiHOME
d½13ðSÞ HODE
dt
¼ k7½LA  k14½13ðSÞ HODE
8>>>><
>>>>:
ð2Þ
Here [x] indicates the concentration of metabolite x. Parameters k1 to k7 describe the conver-
sion of AA and LA to the corresponding downstream metabolites. Parameters k8 to k14 de-
scribe the degradation of these compounds into further downstream metabolites that were not
measured. Reaction parameters are summarized in Table 1. Altogether Model 1 describes the
AA and LA metabolic branches as ﬁrst-order kinetics. As each parameter appears only in one
equation, the parameters can be estimated by solving independently each one of the seven
ODEs. In other words, Equation (1) represents an uncoupled system of ODEs.
Model 2: Pseudo-steady-state model. Model 1 can be simplified assuming a pseudo
steady state [23]: The two processes of AA and LA conversion in the white blood cells and the
dynamics of the blood AA and LA concentration happen on different time scales—hours for
the blood dynamics and seconds for the degradation of AA and LA in the cells. For this reason,
the variation of the downstream products can be considered to be negligible, at each given mea-
surement point [24]. This is equivalent to setting the time derivative term d/dt in Equations (1)
and (2) to 0.
The pseudo-steady-state approximation allows the use of algebraic equations instead of dif-
ferential equations to estimate the reaction parameters starting from the measured concentra-
tion of the chemical species considered. For the sake of simplicity we will indicate with n(t) the
concentration at time t of either AA or LA and with y(t) the concentration of any of their
downstream metabolites (see Equations (1) and (2)) at time t, so that we can write
dy
dt
¼ P  nðtÞ  D  yðtÞ ð3Þ
Table 1. Summary of the reactions and parameters involved in the lumped AA and LA metabolism
under investigation.
No. Reaction Control enzyme Parameter name
1 AA ! 5(S)-HETE 5-LOX, FLAP k1
2 AA ! 15(S)-HETE 15-LOX k2
3 AA ! 11,12-DiHETrE CYP, sEH k3
4 AA ! 14,15-DiHETrE CYP, sEH k4
5 LA ! 9(S)-HODE 15-LOX k5
6 LA ! 9,10-DiHOME CYP, sEH k6
7 LA ! 13(S)-HODE 15-LOX k7
8 5(S)-HETE! k8
9 15(S)-HETE ! k9
10 11,12-DiHETrE ! k10
11 14,15-DiHETrE ! k11
12 9(S)-HODE ! k12
13 9,10-DiHOME ! k13
14 13(S)-HODE ! k14
doi:10.1371/journal.pone.0119856.t001
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where the coefﬁcients P and D (dimension t-1) are the production rate and the degradation rate
for compound y, respectively. In the pseudo-steady-state approximation Equation (3) becomes
0 ¼ P  nðtÞ  D  yðtÞ ð4Þ
From Equation (4) it follows that
yðtÞ ¼ P
D
nðtÞ ð5Þ
that is
yðtÞ ¼ A  nðtÞ ð6Þ
where we have set A = P/D, thus the ratio of the production and degradation rates of
compound y.
The problem is now reduced to the estimation of a single parameter A. This approach en-
ables the complexity of the model to be reduced by reducing the number of parameters to be
estimated from two to one as P and D are not estimated separately but only their ratio: For in-
stance, in the reaction involving the conversion of AA to 5(S)-HETE and its subsequent degra-
dations (see Fig. 1, panel A and Table 1), the two parameters controlling the reaction, k1 and
k8, are not estimated separately but their k1/k8 ratio is estimated.
It should be noted that the pseudo-steady-state approximation leading to Equation (6) im-
plies that y (t) and n (t) are correlated. This means that this approximation is justified if, and
only if, the concentrations of AA and LA are correlated with those of their downstream metab-
olites. As shown in Tables 2 and 3, a strong correlation generally exists between the concentra-
tions of AA and LA and their metabolites for all 12 subjects in the study.
Parameter estimation for Model 1. In general, to be of any practical use, the model
parameters must be determined with sufficient precision to adequately describe the inter-
individual differences in the relative activity of their AA and LA metabolism. The system of dif-
ferential equations can be solved numerically using standard procedures such as the standard
ODE45 solver (MATLAB 2012b, The MathWorks, Inc., Natick, MA, US). As mentioned earli-
er, the systems are uncoupled permitting simple estimation procedures. During this fitting pro-
cess, very large correlations were observed between the estimates of the two parameters
pertaining to a single equation; these estimates were therefore deemed unreliable and not con-
sidered for further analysis. Instead, Model 2 was used.
Parameter estimation for the pseudo-steady-state model. Model 2 requires only the esti-
mation of one parameter: A. This can be easily done by regressing y(t) on n(t). The least-
squares solution for A, that is its estimate Â, is given by
A^ ¼ ðnTnÞ1ðnTyÞ ð7Þ
Ameasure of the precision of the linear regression estimate C^ can be expressed in terms of con-
ﬁdence intervals (CIs). The CIs for the linear regression are given by
A^  tð1 a
2
; n pÞSEðA^Þ ð8Þ
where SE(Â) is the standard error of the coefﬁcient estimate, and t(1–α/2,n—p) is the 100(1–α/2)
percentile of t-distribution with n—p degrees of freedom; n is the number of observations and p
is the number of regression coefﬁcients to be estimated. In the present case n = 6 and p = 1.
Interpretation of the A parameter. The A parameter is defined as the ratio of the produc-
tion rate P and the degradation rate D for compound y (see Equations 5 and 6). For each
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branch, A can be considered as a summary of the information about a) the enzymatic process
controlling the conversion of AA or LA to a specific metabolite, and b) the (possibly enzymatic)
further downstream process that leads to the degradation of this specific metabolite to unmea-
sured compounds. Altogether A can be viewed as a measure of the relative activity of a given
branch of the metabolic pathway of either AA or LA. Nothing can be said about the absolute
values of P and D parameters because the relative nature of the A parameter is not able to
describe scale factors between P and D (see Equations (4) and (5)). Nonetheless, differences in
the values of the A parameter describe inter-individual differences in the relative activity of
these metabolic branches.
Table 2. Correlation values of arachidonic acid (AA) and its downstream metabolites based on six time points for the 12 subjects in the study.
Subject 5(S)-HETE vs AA 15(S)-HETE vs AA 11,12-DiHETrE vs AA 14,15-DiHETrE vs AA
1 0.98 0.83 0.72 0.79
2 0.75 0.92 0.92 0.93
3 0.57 0.59 0.89 0.83
4 0.86 0.80 0.70 0.69
5 0.71 0.76 0.96 0.92
6 0.25 0.69 0.95 0.93
7 0.67 0.90 0.91 0.86
8 0.84 0.82 0.78 0.69
9 0.88 0.91 0.98 0.91
10 0.66 0.70 0.98 0.86
11 0.98 0.86 0.93 0.93
12 0.84 0.65 0.97 0.89
The pseudo-steady-state approximation implies that AA and its four downstream metabolites are correlated as given by Equation (6) in the text.
doi:10.1371/journal.pone.0119856.t002
Table 3. Correlation values of linoleic acid (LA) and its downstream metabolites based on six time
points for the 12 subjects in the study.
Subject 9(S)-HODE vs LA 9,10-DiHOME vs LA 13(S)-HODE vs LA
1 0.61 0.51 0.65
2 0.92 0.85 0.91
3 0.60 0.55 0.61
4 0.81 0.86 0.83
5 0.64 0.58 0.65
6 0.93 0.73 0.87
7 0.78 0.53 0.72
8 0.75 0.63 0.81
9 0.85 0.89 0.89
10 0.69 0.74 0.74
11 0.99 0.97 0.98
12 0.88 0.95 0.90
The pseudo-steady-state approximation implies that LA and its four downstream metabolites are correlated
as given by Equation (6) in the text.
doi:10.1371/journal.pone.0119856.t003
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Comparison of A parameters. Once A parameters are obtained for all subjects and for all
branches of the AA and LA pathways, two kinds of comparison are of interest:
1. Comparing the A parameters of the different branches of the AA and LA pathways within a
subject, and
2. Given a branch of AA or LA pathway, comparing the corresponding A parameters
across subjects.
These two comparisons are intended to provide information about 1) the differential
relative activity of different branches of the AA/LA pathways within a subject, and 2) inter-
individual variability of the relative activity of a specific branch across different subjects. To
compare the relative activity of the different branches (comparison 1), the ratios of the corre-
sponding A parameters can be considered, leading to a grand total of six ratios ( = 4(4–1)/2)
for the AA pathway and three ratios for the LA pathway.
In the jargon of pharmacokinetics and pharmacodynamics, reaction phenotyping measures
the proportion of metabolism that is carried out by different enzymes [25]. In light of this, the
use of the A parameters seems an appropriate choice to quantify the relative activity of different
branches of a metabolic pathway.
The phenotypic parameter A, for the AA and LA metabolic pathways for 12 subjects, ob-
tained through Model 2, is given in Table 4 (for AA) and Table 5 (for LA) with the associated
95% confidence intervals. Fitted curves (using Equation 13) for two selected compounds
(11,12-DiHTrE and 9,10-DiHOME) are shown in Figs. 2 and 3. Fitted curves for the other
compounds are given in file S1 File.
It is important to note that the concentrations of AA are roughly one order of magnitude
larger than those of LA, while the concentrations of the AA metabolites are roughly one order
of magnitude smaller than those of the LA metabolites. Thus the A parameters of the AA me-
tabolites are 102 to 103 times higher than those of the LA metabolites.
In general, if within a subject an A parameter is larger for one metabolite (e.g. 11,12-
DiHETrE) than for another metabolite (e.g. 5(S)-HETE), this means that either the reaction
rate constant k3 for the production (see Table 1) is larger or the reaction rate constant k10 for
the degradation of 11,12-DiHTrE is smaller than the respective reaction rate constants for
5(S)-HETE. Since both 11,12-DiHTrE and 5(S)-HETE are produced from AA, 11,12-DiHETrE
is more abundant than 5(S)-HETE.
For comparison across the subjects, metabolite concentrations cannot be directly derived
from the A parameters due to different substrate (LA or AA) concentrations. Yet the pathway
activities can still be compared between the subjects by setting the A parameters in proportion
to each other. For example, for subject 11 the A parameters and thus the concentrations of
15-HETE and 11,12-DiHTrE differ by a factor of 3, while for subject 4 the A parameters of
15-HETE and 11,12-DiHTrE are similar, meaning that 15(S)-HETE is three times less abun-
dant in subject 11 and present in approximately equal amounts in subject 4, relative to the pro-
duction of 11,12-DiHETrE.
Multivariate analysis. To highlight patterns of (dis)similarity among the subjects, principal
component analysis (PCA) was performed on the Rmatrix obtained by concatenating the ma-
trices of the A parameter estimations for the 12 subjects for both AA and LA metabolic path-
ways (i.e. data in Tables 4 and 5). The Rmatrix has the size 12 × (4 + 3), subjects × variables. As
the A parameters are obtained from the ratio of two quantities (see Equation 6), the logarithm
of R was taken for linearization purposes [26]. The columns of the transformed matrix were
centered to zero mean and scaled to unit variance before PCA. A scree plot [27] test was used to
determine the optimal number of components (two in this case, 70% of variance explained).
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Results and Discussion
Human plasma samples were collected during an OGTT in a previous study and the responses
of LA, AA and their oxidation products were detected in a quantitative manner [9]. The OGTT
induced changes in several oxylipins that are involved in LOX and CYP pathways, namely in
5(S)-HETE, 15(S)-HETE,11,12-DiHETrE and 14,15-DiHETrE, which are derived from AA,
and in 9(S)-HODE, 13(S)-HODE and 9,10-DiHOME, which are derived from LA. These me-
tabolites may play a role in endothelial inflammation and vascular function. In contrast, OGTT
did not induce changes in oxylipins that are involved in the COX pathway.
Table 4. Estimates of the A parameter for Model 2 obtained by linear regression for the four branches of the AA metabolism: 5(S)-HETE, 15(S)-
HETE, 11,12-DiHETrE and 14,15-DiHETrE.
Subject 5(S)-HETE 15(S)-HETE 11,12-DiHETrE 14,15-DiHETrE
1 0.62 ± 0.08 1.08 ± 0.16 1.62 ± 0.41 1.11 ± 0.25
2 0.58 ± 0.22 1.03 ± 0.06 1.91 ± 0.29 1.37 ± 0.24
3 1.01 ± 0.32 0.99 ± 0.23 1.77 ± 0.33 1.26 ± 0.20
4 0.91 ± 0.16 1.31 ± 0.26 1.51 ± 0.43 1.03 ± 0.27
5 0.60 ± 0.14 1.24 ± 0.38 2.09 ± 0.21 1.27 ± 0.20
6 0.56 ± 0.22 0.81 ± 0.23 1.88 ± 0.30 1.24 ± 0.28
7 0.99 ± 0.31 0.91 ± 0.17 1.50 ± 0.32 0.92 ± 0.22
8 1.12 ± 0.24 1.05 ± 0.16 1.95 ± 0.48 1.05 ± 0.26
9 0.73 ± 0.13 0.80 ± 0.13 1.76 ± 0.16 1.24 ± 0.20
10 0.74 ± 0.22 0.78 ± 0.17 1.62 ± 0.33 1.02 ± 0.30
11 0.90 ± 0.05 0.75 ± 0.14 2.21 ± 0.33 1.23 ± 0.19
12 1.06 ± 0.23 1.08 ± 0.23 1.55 ± 0.18 0.93 ± 0.16
Estimates are given together with the associated 95% conﬁdence interval indicated by the lower (Lb) and upper (Ub) bound calculated as given by
Equation (14) in the text. A parameters are × 104.
doi:10.1371/journal.pone.0119856.t004
Table 5. Estimates of the A parameter for Model 2 obtained by linear regression for the three
branches of the LA metabolism: 9(S)-HODE, 9–10-DiHOME and 13(S)-HODE.
Subject 9(S)-HODE 9,10-DiHOME 13(S)-HODE
1 0.59 ± 0.15 0.31 ± 0.07 0.59 ± 0.13
2 0.97 ± 0.13 0.34 ± 0.05 1.10 ± 0.14
3 0.53 ± 0.22 0.38 ± 0.15 0.53 ± 0.19
4 0.87 ± 0.19 0.42 ± 0.07 0.96 ± 0.21
5 0.37 ± 0.15 0.26 ± 0.07 0.41 ± 0.16
6 0.25 ± 0.04 0.15 ± 0.05 0.28 ± 0.05
7 0.62 ± 0.12 0.26 ± 0.08 0.61 ± 0.15
8 0.67 ± 0.18 0.24 ± 0.07 0.66 ± 0.16
9 0.44 ± 0.09 0.26 ± 0.04 0.48 ± 0.09
10 0.63 ± 0.20 0.31 ± 0.09 0.70 ± 0.22
11 0.92 ± 0.15 0.33 ± 0.04 0.98 ± 0.16
12 0.57 ± 0.14 0.17 ± 0.03 0.55 ± 0.13
Estimates are given together with the associated 95% conﬁdence interval indicated by the lower (Lb) and
upper (Ub) bound calculated as given by Equation (14) in the text. A parameters are ×10.
doi:10.1371/journal.pone.0119856.t005
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Following OGTT, significant reductions in AA, LA and their downstream metabolites were
observed after 2 h when compared to baseline and the water control challenge. The concentra-
tions reached control levels after 4–6 h (Figs. 2 and 3 and supplemental file S1 File). The initial
reductions in oxylipins were explained by the reduced release of fatty acids from adipose tissue
and triacylglycerides as a result of the postprandial increase in insulin. As soon as insulin de-
clines, fatty acids are again released into plasma, most likely leading to increases in oxylipins
after 2 hours [13,28]. Significant inter-individual differences in the response of the different
oxylipins upon the OGTT [9] were observed, and we selected this study to derive quantitative
descriptors of phenotypical pathway preferences.
To arrive at phenotypical descriptors of oxylipin metabolism we built a regression model
that incorporates both the time-resolved oxylipin concentrations and the a priori knowledge
on the degradation pathways of AA and LA. This was accomplished by first lumping the meta-
bolic networks of interest. Lumping is a common approach to reducing the dimensionality and
the complexity of a model by preserving its physiological nature in such a way that no useful
information about underlying biological processes is lost [29]. The lumped metabolic networks
are given in Fig. 1.
We obtained phenotypic parameters by regressing, for each individual, the AA and LA
concentration profiles on the corresponding byproducts concentration levels, assuming a
pseudo-steady-state: in this way the problem reduced to the estimation of a single parameter
A. The combination of two or more parameters is a well-known strategy to overcome the prob-
lem of unidentifiable parameters [8,30], and we used it to characterize individual phenotypical
variation of the oxylipins metabolism.
We found that the A parameters between the AA and LA metabolites differed by 2 to 3 or-
ders of magnitude due to higher concentrations of AA when compared to LA and lower con-
centrations of the AA metabolites when compared to the LA metabolites. Thus, LA metabolites
are in general more efficiently produced than AA metabolites.
To get an overview of the pathway-related and phenotypic differences in the AA and LA
metabolism, principal component analysis (PCA) was performed on the phenotypic parame-
ters A that were calculated for the AA (Table 4) and LA (Table 5) metabolites for each of the 12
subjects. From the biplot in Fig. 4 it becomes apparent that the first component is exclusively
described by the LA metabolites, while the second component mostly explains the variation in
AA metabolites. This indicates that the AA and LA pathways are independent. Also the corre-
lation matrix (Fig. 5) calculated on the basis of the A parameters of the AA and LA metabolites
across the subjects shows no strong correlations between the AA and LA metabolites, thus con-
firming that the formation of AA and LA metabolites is not related to each other. This is sur-
prising considering that the same enzymes (LOX, CYP) are involved in the two pathways. For
example, 15(S)-HETE and 13(S)-HODE are formed through the activity of the 15-LOX en-
zyme from AA and LA, respectively. Similarly, the CYP enzyme regulates the formation of
9,10-DiHOME from LA and 11,12-DiHETrE and 14,15-DiHETrE from AA.
We observed a strong inter-individual variation in metabolizing LA with respect to AA. In
contrast, we observed strong correlations between the LA metabolites, meaning that all subjects
metabolized LA in a similar manner, irrespective of the enzyme. (The stronger correlation be-
tween the LOX metabolites than between the LOX and CYP metabolites may still be important
to note.) In comparison to the LA metabolism, we only found a strong positive correlation be-
tween the CYP metabolites of AA and no correlation between the LOX metabolites of AA. This
indicates that AA is metabolized using a common route through the activity of the CYP en-
zyme, while the use of the LOX enzymes is subject to inter-individual variation. The negative
correlations between the CYP and LOX metabolites of AA suggest competition between the
CYP and LOX pathways.
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When ranking the A parameters of the metabolites for each subject within the AA and LA
pathways, respectively, differences between the relative preferences of the AA and LA metabo-
lism were noted. Regarding the AA metabolism, 11,12-DiHETrE had the largest A parameter
for each subject, followed by 14,15-DiHETrE and 15(S)-HETE. 5(S)-HETE in general had the
lowest A parameter, except for subjects 7 and 8. These results show (i) that there is an overall
preference for producing 11,12-DiHETrE and a particular preference for producing 11,12-
DiHETrE over 14,15-DiHETrE within the CYP pathway, and (ii) that the formation of 5(S)-
HETE from AA through the 5-LOX activity is the least preferred pathway for AA metabolism.
This order of relative pathway activity is opposed to the order observed for LA. For each sub-
ject, the A parameters of 9(S)-HODE and 13(S)-HODE were larger than those of 9,10-
DiHOME, showing that the LOX pathways are preferred over the CYP pathway.
Moreover, we noticed significant inter-individual variation in the LA and AA metabolism.
While the individual time curves of the AA and LA and their metabolites (Figs. 2 and 3) appear
similar, the A parameters clearly reveal differences between the subjects. It appears that subjects
1, 3, 8 and 10 metabolized LA and AA in a similar manner, while stronger differences in the
Fig 4. Principal component analysis of the AA and LAmetabolic branches. Biplot for the principal
component analysis of AA and LA branches of the oxylipins metabolism. The first and second components
respectively describe the LA and AA pathways. It should be noted that the 12 subjects tend to spread either
along the first component (LA metabolism) or along the second component (AA metabolism).
doi:10.1371/journal.pone.0119856.g004
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metabolism patterns were observed for the other subjects. For example, subject 2 produced
more 14,15-DiHETrE, 9(S)-HODE and 13(S)-HODE, while subject 12 produced more 5(S)-
HETE relative to all subjects and metabolites. These inter-individual variations in the A param-
eters account for differences in both pathway activity and substrate (LA and AA) concentra-
tions. Inter-individual differences were also observed for the AA and LA metabolism,
respectively. With regard to the LA metabolism, the A parameters for 9(S)-HODE and 13(S)-
HODE are 1.4–3.4 times higher when compared to 9,10-DiHOME. The largest difference was
observed for subjects 12 and 3. While subject 12 produced three times more 9(S)-HODE and
13(S)-HODE than 9,10-DiHOME, subject 3 produced approximately equal amounts of these
metabolites. With regard to the AA metabolism, 5(S)-HETE, 15(S)-HETE and 14,15-DiHETrE
were 1.5–3.5, 1.5–3 and 1.4–1.9 times less abundant than 11,12-DiHETre, thus showing the
strongest inter-individual variation for the two LOX metabolites (S)-HETE and 15(S)-HETE.
For example, subjects 5 and 6 produced 3.5 times less 5(S)-HETE, while subjects 12 and 7 pro-
duced only slightly less of this metabolite when compared to 11,12-DiHETrE. In comparison,
subjects 4 and 11 displayed the smallest and largest difference for 15(S)-HETE relative to
11,12-DiHETrE.
Conclusions
By incorporating a priori knowledge on oxylipin pathways we were able to derive a phenotypi-
cal descriptor that captures the inter-individual differences in AA and LA metabolism in re-
sponse to an OGTT. This was accomplished by defining the A parameter that summarizes
information on the enzymatic processes controlling AA and LA degradation. The simplifica-
tion of the metabolic network and the assumption of a pseudo-steady-state model enable the
modeling of a sparsely sampled response with a straightforward linear regression approach.
Multivariate analysis and correlation analysis shows that there is little or no competition
Fig 5. Correlation among AA and LA parameters. Heat-map for the correlation matrix among the parameters describing AA and LA downstream
metabolism, obtained using the estimated values obtained for the seven A parameters for the 12 subjects. There is no (or very weak) correlations between
the AA and LA metabolites, suggesting that the formation of AA and LAmetabolites is not related to each other.
doi:10.1371/journal.pone.0119856.g005
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between the LA and AA pathways, although the same enzymes are shared between the two
pathways. Yet, the A parameters suggest that within the LA and AA pathways AA is preferably
metabolized to the CYP metabolites (in particular 11,12-DiHETrE), while the LOX pathways
are preferred over the CYP pathway for LA. Comparison of the phenotypic A parameters sug-
gests that the subjects can be stratified on the basis of preferred relative activity of the AA and
LA metabolism.
The method used to derive all the conclusions presented here is linear regression, which is
well understood and easy to apply. But it can only be applied if the pseudo-steady-state as-
sumption holds. If this is not the case then much more complicated numerical approaches
must be used. These approaches are also more demanding in terms of the data quality than
linear regression, but can in principle be used in a similar strategy. In cases where the pseudo-
steady-state assumption was valid, linear regression provided biological insight into the vari-
ability of oxylipin responses.
Supporting Information
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AA and LA byproducts.
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